Reports David Rowland and Sid Ryan Reports David Rowland and Sid Ryan

P.F.I. Profiting from Inflation?

New report shows the significant impact of inflation on NHS Trusts with PFI schemes, with large profits and dividend payments continuing to be made by PFI companies.

Read More
Reports David Rowland and Sid Ryan Reports David Rowland and Sid Ryan

Mapping joint venture businesses in private healthcare

This analysis maps the network of joint venture businesses between NHS medical consultants and private healthcare companies, building on the CHPI’s 2019 report ‘Pounds for Patients’ which looked at financial incentives and conflicts of interest in the UK’s private healthcare system.

Read More
Reports David Rowland Reports David Rowland

How well are conflicts of interest managed in local NHS commissioning in England?

This report looks at how changes to the NHS in England over the past decade have created greater risks of abuses of power, and how reforms to local commissioning are exacerbating them. Since 2012, membership organisations made up of General Practitioners (GPs), called Clinical Commissioning Groups (CCGs), have managed most of the NHS’ budget in England. They are responsible for purchasing £78 billion of healthcare services on behalf of the NHS. At the same time, these same GPs are independent contractors to the NHS and are in receipt of around £8.5 billion of NHS funding each year.

Read More
Reports Vivek Kotecha Reports Vivek Kotecha

Plugging the leaks in the UK care home industry – Strategies for resolving the financial crisis in the residential and nursing home sector

This report identifies where each pound that goes into the care home industry ends up by using a forensic study of the accounts of over 830 adult care home companies, including the 26 largest providers. The companies examined have a combined income of £10.4bn, representing 68% of the total estimated market value for independent providers in 2017.

Read More
Vivek Kotecha & Professor Karl Claxton Vivek Kotecha & Professor Karl Claxton

Who decides the price and availability of NHS medicines?

Outrage and dismay over the prices charged for new medicines are becoming an increasingly regular occurrence in England. Most recently it was over a life-extending drug for cystic fibrosis, Orkambi, with a hefty price tag of £105,000 per patient per year – far higher than NHS England’s counter offer of £500m over 5 years across all patients.

Read More
CHPI Research Team CHPI Research Team

Counting the cost of school PFI schemes

This report extends CHPI’s existing analysis on PFI in the NHS to look at the education sector in England, and potential avenues for saving taxpayers' money.

Read More